HomeCompareMTRAX vs PFE

MTRAX vs PFE: Dividend Comparison 2026

MTRAX yields 2.25% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $26.5K in total portfolio value· pulled ahead in Year 9
10 years
MTRAX
MTRAX
● Live price
2.25%
Share price
$23.34
Annual div
$0.53
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.0K
Annual income
$260.41
Full MTRAX calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MTRAX vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTRAXPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTRAX + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTRAX pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTRAX
Annual income on $10K today (after 15% tax)
$191.38/yr
After 10yr DRIP, annual income (after tax)
$221.35/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,098.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTRAX + PFE for your $10,000?

MTRAX: 50%PFE: 50%
100% PFE50/50100% MTRAX
Portfolio after 10yr
$36.3K
Annual income
$13,259.56/yr
Blended yield
36.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MTRAX
No analyst data
Altman Z
3.6
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTRAX buys
0
PFE buys
0
No recent congressional trades found for MTRAX or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTRAXPFE
Forward yield2.25%6.13%
Annual dividend / share$0.53$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$23.0K$49.6K
Annual income after 10y$260.41$26,258.71
Total dividends collected$2.4K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MTRAX vs PFE ($10,000, DRIP)

YearMTRAX PortfolioMTRAX Income/yrPFE PortfolioPFE Income/yrGap
1$10,925$225.15$9,153$693.39+$1.8KMTRAX
2$11,920$229.89$8,593$849.25+$3.3KMTRAX
3$12,989$234.41$8,336$1,066.78+$4.7KMTRAX
4$14,137$238.72$8,437$1,384.80+$5.7KMTRAX
5$15,369$242.82$9,013$1,875.40+$6.4KMTRAX
6$16,691$246.71$10,306$2,680.72+$6.4KMTRAX
7$18,110$250.42$12,820$4,101.38+$5.3KMTRAX
8$19,632$253.93$17,673$6,826.70+$2.0KMTRAX
9← crossover$21,263$257.25$27,543$12,591.86$6.3KPFE
10$23,012$260.41$49,560$26,258.71$26.5KPFE

MTRAX vs PFE: Complete Analysis 2026

MTRAXStock

The investment seeks current income consistent with reasonable opportunity for future growth of capital and income. The fund normally invests a minimum of 30% of its net assets in equity securities and a minimum of 30% of its net assets in debt securities. From time to time, it may temporarily invest less than 30% of its net assets in equity or debt securities as a result of market conditions, individual securities transactions or cash flow considerations. The fund may invest in investment grade and below investment grade debt securities of varying maturities.

Full MTRAX Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MTRAX vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTRAX vs SCHDMTRAX vs JEPIMTRAX vs OMTRAX vs KOMTRAX vs MAINMTRAX vs JNJMTRAX vs MRKMTRAX vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.